John Foster joins Frontage Laboratories, Inc. as Executive Director, Regional Head of Sales, West
Frontage Announces Full-Service Human Absorption, Metabolism, and Excretion (hAME) Studies with Radiolabeled Compounds at its Clinical Site in Secaucus, NJ.
Frontage to Provide Full Service Human Radiolabeled Absorption, Metabolism, and Excretion Study Capabilities in Early 2021
Mr. Nicholas Pimlett joins Frontage Laboratories, as Vice President of Alliance & Program Management.
Prior to joining Frontage, Nicholas has over 18 years of experience at SANOFI where he held multiple positions of increasing responsibilities. He started his career in the lab as a Bioanalytical Scientist, after he obtained his MBA, he transitioned to Outsourcing Management to support R&D Projects across North America, Europe, and Asia. This scientific and operational experience provided him with an opportunity to serve as the Chief of Staff for the Global Preclinical Dept. and the NA R&D Hub. He then transitioned to a Compliance and Business Operations role in the US before expanding to oversee a global Medical Business Operation and Compliance Organization that managed Financial Regulations in 40+ countries and Compliance Regulations in 85 countries. His most recent position was with TEMPUS LABS as the Associate Vice President of Alliance Management.
Frontage Holdings Announces 2020 Interim Results
Since March 2020, the number of COVID-19 cases continued to rise in the United States, which negatively affected the Group’s business. The global pandemic has limited the full capacity of the Group’s employees performing laboratory services and lowered its delivery efficiency. The Group has employed various mitigation measures focusing on the safety and well-being of its employees, customers and partners, and the continuity of its business operations to minimize the adverse impact of the pandemic. The Group’s facilities in the United States continue to operate at a reduced utilization rate.